Heidi Kempinski

Heidi Kempinski joined Aegle in 2020 as the Senior Vice President and Head of Operations. She is a seasoned operations executive who brings over 25 years of experience in global drug development, with core experience in strategic planning, product development, program management and R&D and business operations. Her experience includes the development of both large and small molecules, spanning all development stages through to commercialization. Ms. Kempinski has successfully built and led integrated R&D operations for companies of variable size and development maturity.

Prior to joining Aegle, Ms. Kempinski served as VP of Business Operations and Strategic Alliances at GSK after their acquisition of TESARO, where she led the overall integration of TESARO into GSK. At TESARO, she was part of the founding team building R&D operations in parallel to in-licensing and operationalization of the company’s first assets. Ms. Kempinski established pharmaceutical development and manufacturing, quality, regulatory, clinical operations, and program management for the company, ultimately leading to multiple, successful development programs, regulatory approvals in >30 countries and product launches in the US and EU. Heidi also managed all global development and commercialization relationships with licensors and licensees, and collaborators/partners for discovery, clinical development, and diagnostics.

Prior to TESARO, Heidi held executive roles in R&D Operations and Program Management at several biopharmaceutical companies including Abraxis BioScience, Eisai, MGI Pharma, Altus Pharmaceuticals, ZYCOS, and Transkaryotic Therapies. Heidi earned a BS in microbiology and chemistry from Quinnipiac University and an MBA with a specialty in innovation and entrepreneurship from Northeastern University.